<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial †</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2015-01-21">21 January 2015</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>Dr</roleName><forename type="first">Charles</forename><forename type="middle">S</forename><surname>Fuchs</surname></persName>
							<email>charles_fuchs@dfci.harvard.edu</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Medical Oncology/Solid Tumor Oncology</orgName>
								<orgName type="department" key="dep2">Dana-Farber Cancer Institute</orgName>
								<address>
									<settlement>Boston</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">S</forename><surname>Azevedo</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Oncology Service</orgName>
								<orgName type="institution">Hospital de Clinicas de Porto Alegre</orgName>
								<address>
									<settlement>Porto Alegre</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">T</forename><surname>Okusaka</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Hepatobiliary and Pancreatic Oncology</orgName>
								<orgName type="institution">National Cancer Center Hospital</orgName>
								<address>
									<settlement>Tokyo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J.-L</forename><surname>Van Laethem</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Gastroenterology</orgName>
								<orgName type="institution">Erasme University Hospital</orgName>
								<address>
									<settlement>Brussels</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Lipton</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Medical Oncology</orgName>
								<orgName type="institution">Royal Melbourne Hospital</orgName>
								<address>
									<settlement>Parkville</settlement>
									<region>VIC</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">H</forename><surname>Riess</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Hematology, Oncology, and Tumor Immunology</orgName>
								<orgName type="institution">Charité University</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Szczylik</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution">Military Institute of Health Services</orgName>
								<address>
									<settlement>Warsaw</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Moore</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Princess Margaret Cancer Centre</orgName>
								<orgName type="institution">University of Toronto</orgName>
								<address>
									<settlement>Toronto</settlement>
									<region>ON</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Peeters</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution">Antwerp University Hospital</orgName>
								<address>
									<settlement>Edegum</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">G</forename><surname>Bodoky</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution">St László Hospital</orgName>
								<address>
									<settlement>Budapest</settlement>
									<country key="HU">Hungary</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Ikeda</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Hepatobiliary and Pancreatic Oncology</orgName>
								<orgName type="institution">National Cancer Center Hospital East</orgName>
								<address>
									<settlement>Kashiwa</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">B</forename><surname>Melichar</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution">Palacký University Medical School and Teaching Hospital</orgName>
								<address>
									<settlement>Olomouc</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">R</forename><surname>Nemecek</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution">Masaryk University Medical School and Masaryk Memorial Cancer Institute</orgName>
								<address>
									<settlement>Brno</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">S</forename><surname>Ohkawa</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Department of Gastroenterology</orgName>
								<orgName type="institution">Kanagawa Cancer Center</orgName>
								<address>
									<settlement>Yokohama</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>´wieboda-Sadlej</surname></persName>
							<affiliation key="aff14">
								<orgName type="department">Department of Haematology, Oncology and Internal Medicine</orgName>
								<orgName type="institution">Medical University of Warsaw</orgName>
								<address>
									<settlement>Warsaw</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Tjulandin</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Department of Clinical Pharmacology and Chemotherapy</orgName>
								<orgName type="institution">Russian Cancer Research Center</orgName>
								<address>
									<settlement>Moscow</settlement>
									<country key="RU">Russia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">E</forename><surname>Van Cutsem</surname></persName>
							<affiliation key="aff16">
								<orgName type="department">Digestive Oncology</orgName>
								<orgName type="institution">University Hospitals Gasthuisberg/Leuven and KU Leuven</orgName>
								<address>
									<settlement>Leuven</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">R</forename><surname>Loberg</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Medical Sciences</orgName>
								<orgName type="institution">Amgen Inc</orgName>
								<address>
									<settlement>Thousand Oaks</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">V</forename><surname>Haddad</surname></persName>
							<affiliation key="aff18">
								<orgName type="institution" key="instit1">Global Biostatistical Science</orgName>
								<orgName type="institution" key="instit2">Amgen Ltd</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Gansert</surname></persName>
							<affiliation key="aff19">
								<orgName type="institution">Global Development</orgName>
								<address>
									<addrLine>Thousand Oaks</addrLine>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Bach</surname></persName>
							<affiliation key="aff20">
								<orgName type="department">Development Oncology Therapeutics</orgName>
								<orgName type="institution">Amgen Inc</orgName>
								<address>
									<settlement>Thousand Oaks</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Carrato</surname></persName>
							<affiliation key="aff21">
								<orgName type="department">Medical Oncology Department</orgName>
								<orgName type="institution">University Hospital Ramon y Cajal</orgName>
								<address>
									<settlement>Madrid</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff22">
								<orgName type="department" key="dep1">Department of Medical Oncology/Solid Tumor Oncology</orgName>
								<orgName type="department" key="dep2">Dana-Farber Cancer Institute</orgName>
								<address>
									<addrLine>Mailstop Dana 1220, 450 Brookline Avenue</addrLine>
									<postCode>02215</postCode>
									<settlement>Boston</settlement>
									<region>MA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial †</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2015-01-21">21 January 2015</date>
						</imprint>
					</monogr>
					<idno type="MD5">7CA20FE8432C49A50605CBC60D6FCBAD</idno>
					<idno type="DOI">10.1093/annonc/mdv027</idno>
					<note type="submission">Received 5 November 2014; revised 29 December 2014; accepted 30 December 2014</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:10+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>ClinicalTrials.gov NCT01231347 ganitumab</term>
					<term>gemcitabine</term>
					<term>pancreatic cancer</term>
					<term>IGF-1 receptor</term>
					<term>biomarker</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: This double-blind, phase 3 study assessed the efficacy and safety of ganitumab combined with gemcitabine as first-line treatment of metastatic pancreatic cancer.</s></p><p><s>Patients and methods: Patients with previously untreated metastatic pancreatic adenocarcinoma were randomly assigned 2 : 2 : 1 to receive intravenous gemcitabine 1000 mg/m 2 (days 1, 8, and 15 of each 28-day cycle) plus placebo, ganitumab 12 mg/kg, or ganitumab 20 mg/kg (days 1 and 15 of each cycle).</s><s>The primary end point was overall survival (OS).</s><s>Secondary end points included progression-free survival (PFS), safety, and efficacy by levels of circulating biomarkers.</s></p><p><s>Results: Overall, 322 patients were randomly assigned to placebo, 318 to ganitumab 12 mg/kg, and 160 to ganitumab 20 mg/kg.</s><s>The study was stopped based on results from a preplanned futility analysis; the final results are reported.</s><s>Median OS was 7.2 months [95% confidence interval (CI), 6.3−8.2] in the placebo arm, 7.0 months (95% CI, 6.2−8.5) in the ganitumab 12-mg/kg arm [hazard ratio (</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>first-line treatment of metastatic pancreatic cancer <ref type="bibr" target="#b2">[4,</ref><ref type="bibr" target="#b3">5]</ref>.</s><s>Despite newer regimens (e.g.</s><s>FOLFIRINOX and nab-paclitaxel plus gemcitabine <ref type="bibr" target="#b4">[6,</ref><ref type="bibr" target="#b5">7]</ref>), patient outcomes in first-line settings are unsatisfactory.</s><s>Whereas targeted therapies are available for other tumor types, an unmet need remains for targeted treatments of metastatic pancreatic cancer.</s></p><p><s>The insulin-like growth factor (IGF)-1 receptor (IGF1R) pathway is a potential therapeutic target for pancreatic cancer, given the frequent overexpression in pancreatic tumors of IGF1R and its ligands IGF-1 and IGF-2 <ref type="bibr" target="#b6">[8]</ref><ref type="bibr" target="#b7">[9]</ref><ref type="bibr" target="#b8">[10]</ref>.</s><s>Ganitumab, an investigational, fully human, monoclonal antibody antagonist of IGF1R, prevents binding of IGF-1 and IGF-2 to IGF1R <ref type="bibr" target="#b9">[11]</ref>.</s><s>In a randomized phase 2 study, ganitumab combined with gemcitabine had manageable toxicity and showed a trend toward improved overall survival (OS; hazard ratio [HR], 0.67; P = 0.12) and progression-free survival (PFS; HR, 0.65; P = 0.072) compared with placebo in patients with metastatic pancreatic adenocarcinoma <ref type="bibr" target="#b10">[12]</ref>.</s></p><p><s>GAMMA (Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas), a randomized, double-blind, placebo-controlled, phase 3 study, assessed the efficacy and safety of ganitumab combined with gemcitabine in first-line treatment of metastatic pancreatic adenocarcinoma.</s><s>We report the final results of GAMMA, which was stopped early after a preplanned futility analysis demonstrated that a positive outcome was unlikely at primary analysis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>patients and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>patients</head><p><s>GAMMA was conducted at 146 centers.</s><s>Eligible patients (≥18 years) had previously untreated histologically or cytologically confirmed metastatic pancreatic adenocarcinoma; Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1; and adequate hematologic, renal, hepatic, and cardiac function.</s><s>Exclusion criteria were histology other than pancreatic adenocarcinoma; central nervous system metastases; external biliary drain; paracentesis or thoracentesis for malignant effusion within previous 14 days; prior or synchronous malignancy (except treated or inactive nonmelanoma skin cancer, lentigo maligna, cervical carcinoma, or prostatic intraepithelial neoplasia or malignancy cured ≥3 years); major or minor surgery within previous 30 or 7 days, respectively; and any previous systemic treatment of pancreatic cancer including adjuvant therapy.</s><s>All patients provided written informed consent.</s><s>The study protocol was approved by each site's ethics committee.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>study design and treatment</head><p><s>Patients were randomly assigned 2 : 2 : 1 to receive intravenous gemcitabine 1000 mg/m 2 plus either placebo, ganitumab 12 mg/kg, or ganitumab 20 mg/ kg.</s><s>Selected doses of ganitumab were based on a phase 2 exposure-response analysis <ref type="bibr" target="#b11">[13]</ref>.</s><s>Randomization was stratified by ECOG PS (0 versus 1), liver metastases (yes versus no), and region (Australia, Western Europe, USA, and Canada versus rest of world).</s><s>Patients received gemcitabine on days 1, 8, and 15, and placebo/ganitumab on days 1 and 15 of each 28-day cycle.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>dose adjustments</head><p><s>Gemcitabine could be withheld or reduced depending on timing and toxicity severity; ganitumab was withheld until gemcitabine was resumed.</s><s>Ganitumab dose reductions up to 50% were allowed for toxicity; reductions were permanent.</s><s>Ganitumab could be withheld or permanently discontinued for certain adverse events (AEs).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>tumor assessment</head><p><s>Tumor response was based on investigator assessment ( per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1 <ref type="bibr" target="#b12">[14]</ref>) of computed tomography or magnetic resonance imaging every 8 weeks.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>safety assessment</head><p><s>All AEs occurring from enrollment until safety follow-up (30 days after the final treatment dose) were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.</s><s>Clinical and laboratory assessments were performed at screening, day 1 of each cycle, and safety follow-up.</s><s>Serum for assessment of anti-ganitumab antibodies <ref type="bibr" target="#b13">[15]</ref> was collected on day 1 of cycles 1, 3, and 7 and at safety follow-up.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>biomarker analysis</head><p><s>In a phase 2 study, ganitumab treatment was associated with enhanced OS in patients with higher baseline circulating total IGF-1, IGF-2, and IGF-binding protein-3 (IGFBP-3) and lower IGFBP-2 <ref type="bibr" target="#b14">[16]</ref>.</s><s>For biomarker assessment, serum was collected predose on days 1 and 8 of cycle 1; on day 1 of cycles 2, 3, 5, 7, and 9; and at safety follow-up.</s><s>Serum baseline total IGF-1 as well as IGFBP-2 and -3 were measured using a competitive binding radioimmunoassay <ref type="bibr" target="#b13">[15]</ref> and immunoassays <ref type="bibr" target="#b14">[16]</ref>, respectively.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>statistical analysis</head><p><s>The primary end point was OS (time from randomization to death); patients living at the date of analysis were censored at the last date known alive.</s><s>Key secondary end points included PFS per RECIST version 1.1 <ref type="bibr" target="#b12">[14]</ref>, OS at 12 months, objective response rate (ORR), duration of response (DOR), and incidence of AEs and laboratory abnormalities.</s><s>Exploratory end points included pharmacodynamic response biomarkers (serum circulating IGF-1, IGFBP-2, and IGFBP-3).</s></p><p><s>The planned sample size was 825 patients.</s><s>The primary analysis was scheduled after 642 deaths to provide 90% and 95% power to detect HRs of 0.73 and 0.65 for the ganitumab 12-and 20-mg/kg arms, respectively, with a one-sided significance level of 0.0125.</s><s>The full analysis set and safety analysis set included all randomized patients, and all patients who received ≥1 dose of ganitumab or placebo, respectively.</s><s>A planned interim efficacy futility analysis of OS was scheduled after ∼30% of events (188 deaths: 156 and 118 for ganitumab 12 and 20 mg/kg, respectively).</s><s>An independent data monitoring committee reviewed the interim safety and efficacy analyses.</s></p><p><s>OS and PFS were compared using log-rank tests stratified by the randomization factors and Kaplan-Meier estimates.</s><s>Cox proportional hazards models stratified by the randomization factors estimated HRs and two-sided 95% CIs for OS, PFS, and DOR.</s><s>ORR differences and odds ratios (OR) between ganitumab and placebo arms were calculated.</s><s>Median DOR was calculated for each treatment arm.</s><s>Descriptive statistics are reported for safety data.</s><s>Treatment effects in each biomarker group and interactions were estimated using a Cox proportional hazards model.</s><s>Amgen Inc. and Axio Research (Seattle, WA, USA) conducted the statistical analyses in collaboration with the co-authors.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>results patients</head><p><s>Between April 2011 and August 2012, 800 patients were randomized (placebo, n = 322; ganitumab 12 mg/kg, n = 318; ganitumab 20 mg/kg, n = 160).</s><s>Patients' characteristics were balanced across treatment arms; 8%-9% of all patients had previously undergone surgery for pancreatic adenocarcinoma with curative intent (Table <ref type="table" target="#tab_0">1</ref>).</s><s>Overall, 792 patients (99%) received ≥1 treatment dose and were included in the safety analysis (supplementary Figure <ref type="figure" target="#fig_1">S1</ref>, available at Annals of Oncology online).</s><s>The study was stopped early (8 August 2012) following a preplanned interim analysis (2 August 2012) that, after crossing the futility boundaries, indicated a positive outcome was unlikely at the primary analysis.</s><s>All patients then discontinued ganitumab and were subsequently managed with other therapies at their physicians' discretion.</s><s>Post-trial therapy was not a trial end point and was not captured following safety follow-up.</s></p><p><s>exposure</s></p><p><s>The median number of cycles for placebo or ganitumab treatment was 3; the median number of gemcitabine cycles was 4 and 3 in the placebo and ganitumab arms, respectively.</s><s>The median relative dose intensity of ganitumab was ∼1.0; median relative dose intensity of gemcitabine was consistent among treatment arms (supplementary      <ref type="table" target="#tab_3">S2</ref>, available at Annals of Oncology online).</s></p><p><s>Objective response was evaluable by the investigators in 769 patients (96%) with measurable disease at baseline (supplementary Table <ref type="table">S3</ref>, available at Annals of Oncology online).</s><s>ORR was 10% in the placebo arm, 16% in the ganitumab 12-mg/kg arm (OR, 1.69; 95% CI, 1.02−2.81),</s><s>and 15% in the ganitumab 20-mg/kg arm (OR, 1.51; 95% CI, 0.80−2.81).</s><s>The median DOR was 5.6 months (95% CI, 4.1−7.3) in the ganitumab 12-mg/kg arm and 5.5 months (95% CI, 2.1−9.3) in the ganitumab 20-mg/kg arm, compared with 3.0 months (95% CI, 1.9−5.5) in the placebo arm.</s><s>In an ad hoc analysis using a stratified Cox proportional hazards model, the HR for DOR in the ganitumab 12-mg/kg arm versus the placebo arm was 0.49 (95% CI, 0.27 −0.89; P = 0.019), and the HR for the ganitumab 20-mg/kg arm versus the placebo arm was 0.71 (95% CI, 0.30−1.56;</s><s>P = 0.404).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>safety</head><p><s>The incidence of treatment-emergent AEs is summarized in Table <ref type="table" target="#tab_3">2</ref>. AEs (any grade) occurring with a ≥5% greater incidence among all ganitumab-treated patients compared with placebo include hyperglycemia (22% versus 10%), thrombocytopenia (38% versus 30%), fatigue (36% versus 29%), vomiting (28% versus 23%), and diarrhea (23% versus 18%).</s><s>The rates of treatment-emergent venous/arterial thromboembolic events were each ≤4% in each arm; the pulmonary embolism rate was balanced between arms and likewise ≤4% in each arm.</s><s>Grade 3 and 4 treatment-emergent AEs occurred in 176 patients (56%) in the placebo arm, 214 (68%) in the ganitumab 12-mg/kg arm, and 94 (59%) in the ganitumab 20-mg/kg arm.</s><s>AEs resulting in discontinuation of placebo, ganitumab, and/or gemcitabine occurred in 37 patients (12%) who received placebo, 48 (15%) who received ganitumab 12 mg/kg, and 17 (11%) who received ganitumab 20 mg/kg.</s><s>Overall, on-treatment fatal AEs occurred in 33 patients (10%) who received placebo, 30 (10%) who received ganitumab 12 mg/kg, and 18 (11%) who received ganitumab 20 mg/kg.</s><s>Two patients who received placebo had fatal AEs attributed by the investigators to gemcitabine (anemia and cardiac failure); two patients had fatal AEs attributed to ganitumab (cardiac failure and thrombotic thrombocytopenia purpura).</s><s>Of 466 patients who received ganitumab with available serum samples, 18 (4%) developed anti-ganitumab-binding antibodies; no anti-ganitumab-neutralizing antibodies were detected.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>biomarker assessment</head><p><s>Circulating pharmacodynamic biomarkers were assessed in 582 patients (73%; placebo, n = 243; ganitumab 12 mg/kg, n = 226; ganitumab 20 mg/kg, n = 113).</s><s>Baseline circulating levels of total IGF-1, IGFBP-2, and IGFBP-3 were similar across treatment arms</s></p><p><s>(supplementary Figure <ref type="figure">S2</ref>, available at Annals of Oncology online).</s><s>Dividing patients into high and low subgroups based on whether their baseline levels of IGF-1, IGFBP-2, and IGFBP-3 were above or below median, respectively, did not result in a treatment effect on OS or PFS by ganitumab (supplementary Figure <ref type="figure">S3</ref>, available at Annals of Oncology online).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>discussion</head><p><s>GAMMA was stopped early after a prespecified interim analysis indicated that the primary objective was unlikely to be met.</s><s>The final results did not demonstrate improved efficacy by the addition of ganitumab to gemcitabine.</s><s>Numerous other phase 3 studies have also failed to demonstrate clinical benefit from targeted therapies in metastatic pancreatic cancer <ref type="bibr" target="#b15">[17]</ref>.</s><s>These results are disappointing given the encouraging phase 2 study in which ganitumab 12 mg/kg combined with gemcitabine was associated with marginally improved 6-month survival (57% versus 50%) and improved OS (8.7 versus 5.9 months; HR, 0.64; P = 0.12) <ref type="bibr" target="#b10">[12]</ref>.</s></p><p><s>In the placebo, ganitumab 12-mg/kg, and ganitumab 20-mg/kg arms, median OS (7.2, 7.0, and 7.1 months) and PFS (3.7, 3.6, and 3.7 months) were similar to those in the gemcitabine-based control arms of other metastatic pancreatic cancer trials <ref type="bibr" target="#b4">[6,</ref><ref type="bibr" target="#b16">18]</ref>.</s><s>In the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT), compared with placebo, nab-paclitaxel combined with gemcitabine improved median OS (8.5 versus 6.7 months), PFS (5.5 versus 3.7 months), and ORR (23% versus 7%) <ref type="bibr" target="#b4">[6]</ref>.</s><s>Median OS and PFS (11.1 and 6.4 months, respectively) were also longer in a phase 3 study of first-line FOLFIRINOX in patients with metastatic pancreatic cancer than in GAMMA <ref type="bibr" target="#b16">[18]</ref>.</s></p><p><s>Early clinical data identified circulating IGF-1 as a predictive biomarker candidate for the anti-IGF1R monoclonal antibody figitumumab <ref type="bibr" target="#b17">[19]</ref>.</s><s>An analysis of phase 2 data suggested that high median baseline circulating total IGF-1, IGF-2, and IGFBP-3 (and low baseline circulating IGFBP-2) predicted the treatment effect of ganitumab combined with gemcitabine in patients with metastatic pancreatic cancer <ref type="bibr" target="#b14">[16]</ref>.</s><s>In GAMMA, dichotomization of patients based on median biomarker values did not reveal a treatment effect on OS or PFS by ganitumab combined with gemcitabine.</s><s>Possibly, the median serum baseline level was not ideal to separate the high and low subgroups <ref type="bibr" target="#b14">[16]</ref>.</s><s>In the phase 3 Avastin and Tarceva in Advanced Pancreatic Cancer (AViTA) study, which did not meet its primary objective of increasing OS <ref type="bibr" target="#b18">[20]</ref>, improved OS and PFS was associated with the singlenucleotide polymorphism rs9582036 <ref type="bibr" target="#b19">[21]</ref>.</s><s>These results and other large studies of unselected patients with initially disappointing results underscore the need for validated predictive biomarkers for patient selection in trials of IGF1R-targeted therapies <ref type="bibr" target="#b20">[22]</ref>.</s></p><p><s>The underlying cause of the lack of improved efficacy by ganitumab combined with gemcitabine is unclear.</s><s>Although this randomized phase 3 trial failed to meet its primary end point, the original decision to proceed with the trial was based on extensive preclinical data linking the IGF pathway to pancreatic cancer pathogenesis and progression, as well as on the results of a completed randomized phase 2 trial suggesting a potential OS benefit (median OS, 8.7 versus 5.9 months for gemcitabine with ganitumab versus gemcitabine alone, respectively; stratified HR, 0.67; P = 0.12) <ref type="bibr" target="#b10">[12]</ref>.</s><s>Given the magnitude of the unmet need and the novelty of the mechanism of action, this phase 3 trial sought to bring forward a possible breakthrough therapy.</s><s>Patients' characteristics were balanced across treatment arms and were generally consistent with the MPACT and FOLFIRINOX studies <ref type="bibr" target="#b4">[6,</ref><ref type="bibr" target="#b16">18]</ref>.</s><s>Pancreatic adenocarcinoma is a heterogeneous disease characterized by several activating gene mutations <ref type="bibr" target="#b21">[23]</ref>.</s><s>Among these, KRAS mutations, present in ∼95% of pancreatic adenocarcinomas, appear to be an initiating event <ref type="bibr" target="#b21">[23,</ref><ref type="bibr" target="#b22">24]</ref>.</s><s>The analysis of interactions between the IGF1R pathway and pathways downstream of KRAS (e.g.</s><s>MEK <ref type="bibr" target="#b23">[25]</ref>) during malignant transformation may help identify patients responsive to IGF1R-targeted therapy.</s><s>Furthermore, combined targeting of IGF1R and other signaling pathways may be necessary to overcome potential resistance mechanisms <ref type="bibr" target="#b24">[26]</ref>, which may have played a role in GAMMA.</s></p><p><s>The safety profile of ganitumab plus gemcitabine was consistent with earlier observations <ref type="bibr" target="#b10">[12,</ref><ref type="bibr" target="#b13">15]</ref>; no unexpected toxicities were observed.</s><s>The most frequent AEs in GAMMA (e.g.</s><s>nausea, neutropenia, thrombocytopenia, and fatigue) and other AEs of potential concern (e.g.</s><s>hyperglycemia) are easily managed and have been observed in previous ganitumab studies and with other IGF1R pathway-targeted agents <ref type="bibr" target="#b10">[12,</ref><ref type="bibr" target="#b25">27,</ref><ref type="bibr" target="#b26">28]</ref>.</s></p><p><s>In conclusion, ganitumab combined with gemcitabine was not associated with improved OS compared with gemcitabine alone in this unselected patient population with metastatic pancreatic cancer.</s><s>Dichotomization of patients based on median values of potential circulating biomarkers did not demonstrate an enriched treatment effect on OS or PFS.</s><s>Without a validated biomarker to guide patient selection, IGF1R-targeted therapy is not recommended for metastatic pancreatic cancer.</s><s>acknowledgements</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure1.</s><s>Kaplan-Meier curves for overall survival (A) and progression-free survival (B) by treatment group in the full analysis set.</s><s>Patients who had not died (A) or who had not progressed or died (B) at the date of their last assessment were censored.</s><s>Q2W: every 2 weeks.</s><s>a Cox proportional hazards model adjusted for stratification covariates (Eastern Cooperative Oncology Group performance status, 0 or 1; presence of liver metastases, yes or no).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc><div><p><s>baseline prognostic factors (supplementary Table</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Patients' demographics and baseline characteristics a</s></p></div></figDesc><table><row><cell>Placebo + gemcitabine</cell><cell>Ganitumab 12 mg/kg +</cell><cell>Ganitumab 20 mg/kg +</cell></row><row><cell>(n = 322)</cell><cell>gemcitabine (n = 318)</cell><cell>gemcitabine (n = 160)</cell></row></table><note><p><s>a Full analysis set.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head></head><label></label><figDesc><div><p><s>Table S1, available at Annals of Oncology online).</s></p></div></figDesc><table><row><cell>efficacy</cell></row><row><cell>At the final analysis, 513 patients (64%) had died ( placebo,</cell></row><row><cell>n = 201; ganitumab 12 mg/kg, n = 211; ganitumab 20 mg/kg,</cell></row><row><cell>n = 101). Median OS was 7.2 months (95% confidence interval</cell></row><row><cell>(CI), 6.3−8.2) in the placebo arm, 7.0 months (95% CI, 6.2−8.5)</cell></row><row><cell>in the ganitumab 12-mg/kg arm (HR, 1.00; 95% CI, 0.82−1.21;</cell></row><row><cell>P = 0.494), and 7.1 months (95% CI, 6.4−8.5) in the ganitumab</cell></row><row><cell>20-mg/kg arm (HR, 0.97; 95% CI, 0.76−1.23; P = 0.397; Figure 1).</cell></row><row><cell>Median PFS was 3.7 months (95% CI, 3.6−4.4) in the placebo</cell></row><row><cell>arm, 3.6 months (95% CI, 3.4−3.8) in the ganitumab 12-mg/kg</cell></row><row><cell>arm (HR, 1.00; 95% CI, 0.84−1.20; P = 0.520), and 3.7 months</cell></row><row><cell>(95% CI, 3.2−5.0) in the ganitumab 20-mg/kg arm (HR, 0.97;</cell></row><row><cell>95% CI, 0.77−1.22; P = 0.403; Figure 1). Consistent OS and PFS</cell></row><row><cell>results were observed using multivariate models adjusted for</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Summary of treatment-emergent adverse events</s></p></div></figDesc><table><row><cell>AEs, a n (%)</cell><cell cols="3">Placebo + gemcitabine (n = 317)</cell><cell cols="2">Ganitumab 12 mg/kg +</cell><cell></cell><cell cols="2">Ganitumab 20 mg/kg +</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">gemcitabine (n = 315)</cell><cell></cell><cell cols="2">gemcitabine (n = 160)</cell><cell></cell></row><row><cell></cell><cell>All grades</cell><cell>Grade 3</cell><cell cols="2">Grade 4 All grades</cell><cell>Grade 3</cell><cell cols="4">Grade 4 All grades Grade 3 Grade 4</cell></row><row><cell>Any b</cell><cell>312 (98)</cell><cell cols="2">123 (39) 53 (17)</cell><cell>308 (98)</cell><cell cols="2">155 (49) 59 (19)</cell><cell>159 (99)</cell><cell>78 (49)</cell><cell>16 (10)</cell></row><row><cell>Nausea</cell><cell>128 (40)</cell><cell>7 (2)</cell><cell>1 (&lt;1)</cell><cell>133 (42)</cell><cell>5 (2)</cell><cell>0 (0)</cell><cell>71 (44)</cell><cell>2 (1)</cell><cell>0 (0)</cell></row><row><cell>Neutropenia</cell><cell>109 (34)</cell><cell cols="2">51 (16) 14 (4)</cell><cell>117 (37)</cell><cell cols="2">54 (17) 20 (6)</cell><cell>52 (33)</cell><cell>26 (16)</cell><cell>5 (3)</cell></row><row><cell>Thrombocytopenia</cell><cell>94 (30)</cell><cell>16 (5)</cell><cell>5 (2)</cell><cell>126 (40)</cell><cell>23</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>The authors acknowledge the patients (and their families) who participated in GAMMA, the global network of GAMMA investigators, and Benjamin Scott, PhD, and James Balwit, MS, whose work was funded by Amgen Inc., for assistance in writing this manuscript.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>original articles</head><p><s>Annals of Oncology bureau for Amgen Inc., Bayer, Sanofi, and Merck; and has received research funding from Amgen Inc. and Roche.</s><s>GB has served as an advisor/consultant for Amgen Inc., Eli Lilly, and Nordic; and has received compensation for travel from Pfizer and Novartis.</s><s>BM has received honoraria from Amgen Inc., Roche, Novartis, Astellas, GlaxoSmithKline, and Bayer; has served as an advisor/consultant for Roche, Novartis, Astellas, Bayer, and GlaxoSmithKline; and has received travel, accommodations, or expenses from Novartis, Roche, and Janssen.</s><s>RN has received research funding from Amgen Inc. SAT has served on speakers' bureau for Sanofi Aventis, Novartis, Merck, and AstraZeneca; and has received research funding from Sanofi, Novartis, Merck, and AstraZeneca.</s><s>EVC has received research funding from Amgen Inc. RL is employed by and owns stock in Amgen Inc. VH is employed by and owns stock in Amgen Ltd.</s><s>JLG is employed by and owns stock in Amgen Inc. BB is employed by and owns stock in Amgen Inc. and has received compensation for travel from Amgen Inc. AC has participated in advisory boards for Amgen Inc. Bayer, Celgene, Roche, Eli Lilly, and Merck; and has received research funding from Amgen Inc.</s><s>All remaining authors have declared no conflicts of interest.</s><s>references</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0" />			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Trends in the treatment and outcome of pancreatic cancer in the United States</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">N</forename><surname>Baxter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Whitson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Tuttle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Surg Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="1320" to="1326" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma</title>
		<author>
			<persName><forename type="first">M</forename><surname>Tempero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Plunkett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ruiz</forename><surname>Van Haperen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="3402" to="3408" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title level="m" type="main">NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma v.1.2014. Fort Washington, PA: National Comprehensive Cancer Network</title>
		<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up</title>
		<author>
			<persName><forename type="first">T</forename><surname>Seufferlein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Bachet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Van Cutsem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rouqier</surname></persName>
		</author>
		<author>
			<persName><surname>Esmo Guidelines Working</surname></persName>
		</author>
		<author>
			<persName><surname>Group</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="33" to="40" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine</title>
		<author>
			<persName><forename type="first">Von</forename><surname>Hoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Ervin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Arena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="page" from="1691" to="1703" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">Abraxane ® (nab-paclitaxel). Full Prescribing Information</title>
		<imprint>
			<date type="published" when="2013">2013</date>
			<publisher>Celgene Corporation</publisher>
			<pubPlace>Summit, NJ</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Targeting the insulin growth factor receptor 1</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">I</forename><surname>Arnaldez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Helman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hematol Oncol Clin North Am</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="527" to="542" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles</title>
		<author>
			<persName><forename type="first">U</forename><surname>Bergmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Funatomi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yokoyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G</forename><surname>Beger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Korc</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="2007" to="2011" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma</title>
		<author>
			<persName><forename type="first">A</forename><surname>Hakam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Karl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Coppola</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dig Dis Sci</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="1972" to="1978" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Beltran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mitchell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">A</forename><surname>Chung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cancer Ther</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="1095" to="1105" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Kindler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Richards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Garbo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="2834" to="2842" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Exposure-response (E-R) analysis to facilitate phase III (P3) dose selection for ganitumab (GAN, AMG 479) in combination with gemcitabine (G) to treat metastatic pancreatic cancer (mPC)</title>
		<author>
			<persName><forename type="first">J</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Tang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page">4049</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada</title>
		<author>
			<persName><forename type="first">P</forename><surname>Therasse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Arbuck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Eisenhauer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="205" to="216" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Tolcher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sarantopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Patnaik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="5800" to="5807" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor</title>
		<author>
			<persName><forename type="first">I</forename><surname>Mccaffery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tudor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Deng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="4282" to="4289" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Pancreatic cancer: is combination treatment better?</title>
		<author>
			<persName><forename type="first">J</forename><surname>Furuse</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Pract</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="695" to="700" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer</title>
		<author>
			<persName><forename type="first">T</forename><surname>Conroy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Desseigne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ychou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">364</biblScope>
			<biblScope unit="page" from="1817" to="1825" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Correlation of plasma levels of free insulinlike growth factor 1 and clinical benefit of the IGF-IR inhibitor figitumumab (CP-751, 871)</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Hixon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gualberto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Demers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page">3539</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer</title>
		<author>
			<persName><forename type="first">E</forename><surname>Van Cutsem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">L</forename><surname>Vervenne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bennouna</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="2231" to="2237" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials</title>
		<author>
			<persName><forename type="first">D</forename><surname>Lambrechts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Claes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Delmar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="724" to="733" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology</title>
		<author>
			<persName><forename type="first">M</forename><surname>Pollak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="40" to="50" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Genetics and biology of pancreatic ductal adenocarcinoma</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Hezel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Kimmelman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">Z</forename><surname>Stanger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Bardeesy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Depinho</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genes Dev</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1218" to="1249" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes</title>
		<author>
			<persName><forename type="first">C</forename><surname>Almoguera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Shibata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Forrester</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="549" to="554" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">KRAS(G12D)-and BRAF (V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ ERK-stimulated IGF1R signaling</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">A</forename><surname>Appleman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Ahronian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Klimstra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Lewis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cancer Res</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="1228" to="1239" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Insulin-like growth factor receptor inhibitors: baby or the bathwater?</title>
		<author>
			<persName><forename type="first">D</forename><surname>Yee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="page" from="975" to="981" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors</title>
		<author>
			<persName><forename type="first">F</forename><surname>Atzori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tabernero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cervantes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="6304" to="6312" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Cohn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tabernero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Maurel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1777" to="1785" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
